Recent Posts

I'm not sure we know that Anvisa believes that, given what the article says. The statement is made with no precise attribution (just to unknown 'experts'). It may have come from the Biomm CEO. Or just be something the reporter read on the web, as part of the background for the article.

riotimesonline.com/brazil-news/brazil/anvisa-approves-first-inhaled-insulin-in-brazil/

[More at the link.]

According to experts, although it represents an alternative for treating diabetes and a benefit in quality of life by reducing the number of injections, Afrezza has limitations. It is unable to replace all daily insulin applications, it has a limited range of dosage and is unsuitable for patients with lung conditions and those under eighteen years of age.

On the other hand, it is easier to carry and store as it does not require refrigeration and may reduce the number of needle pricks that the patient has to undergo daily.

Inhaled insulin may only replace fast-acting or ultra-fast insulin applications, also called “bolus”. This type of insulin is typically used before each meal when the body needs a larger amount to compensate for sugar intake.

The other type of insulin, “basal”, of slower action, is generally used only once daily and cannot be replaced by the inhaled drug, as explained by Lívia Porto, an endocrinologist at the Centro Especializado em Obesidade e Diabetes of Hospital Alemão Oswaldo Cruz, which specializes in treating obesity and diabetes.

“If a diabetic patient is treated using this basal-bolus therapy, he or she typically takes at least four injections a day: one basal and three boluses, for breakfast, lunch, and dinner. Switching to an inhaler would reduce it from four daily doses to one. It would be a gain in quality of life, although it would not entirely replace the injection”, says the doctor.

For Heraldo Marchezini, CEO of Biomm, the company responsible for product distribution in Brazil, Afrezza’s ease of handling and use represents an improvement in the quality of life of patients. “At mealtimes, the patient often needs to use insulin in a social environment outside the home. The inhalable solution can be faster and more discreet. The inhaler fits in the palm of your hand. It’s a great innovation in terms of use,” he says.

He asserts that the product is suitable for type 1 and 2 diabetes patients. Nevertheless, considering that most type 2 diabetics are treated with pills and not with insulin, the main beneficiaries of the new product would be type 1 diabetic patients, who must obligatorily be treated with insulin.

“In the case of type 2 diabetics, Afrezza would be recommended only for patients who are unable to control blood glucose by only using oral medication,” explains endocrinologist Freddy Eliaschewitz, scientific advisor to the Brazilian Society of Diabetes and director of the Clinical Research Center CPclin, a Brazilian institution that participated in studies on inhaled insulin. According to the specialist, of the approximately 15 million Brazilians suffering from diabetes, it is estimated that 10 percent suffer from type 1 diabetes and 90 percent from type 2.

Many people will smoke cigarettes and put up with a cough because of the immediate nicotine pleasure. Not to mention, they are addictive.

Maybe Afrezza powder should have nicotine added, or be caffeinated? (Just joking, though it might help with retention.)

As I remarked before, that poster is a Brazilian daily newspaper that tweets different often random items about 1,000 times a day (I mean that literally, it really does tweet that much). 

The items listed are all significant, but I'm not so sure that so many of them are unambiguously good. For instance, results and progress reports needn't be good (they could be serious downers), and publications may not be in 'major' journals. Regarding the latter point, the publication experience to date suggests that forthcoming articles might appear in second (or third) tier places. (I'm not saying these things are more likely to be bad than good, just that a lot of them could be sort of a wash / neutral.)

I guess it is a case of 'Hope for the best, plan for the worst'.

Translation of medicafitdiabetica's comment:

I made a summary of this news! Read it calmly, but the excitement is inevitable, right? (I.e.
.
Afrezza®, an ultra-rapid inhaled insulin for pre-meal use, was registered today by ANVISA.
.
Commercialized in the United States since its approval by the FDA in 2015, it will be available in Brazil until the fourth quarter of this year.
.
Supplied with a small, discreet, easy-to-use inhaler, it is given at the beginning of the meal. Afrezza®️ dissolves rapidly after inhalation into the lung and immediately reaches the bloodstream. Maximum insulin levels are achieved within 12 to 15 minutes after administration and decline by approximately 180 minutes.
.
In addition, Afrezza®️ has, among all the insulins available on the market, the action profile that most resembles physiological insulin, since the absorption pathway (lung) and form (insulin monomers) allow absorption and action of insulin more quickly than the others.
.
It is worth noting that Afrezza® should be used in combination with long acting insulin in patients with type 1 diabetes. Afrezza® is not recommended for the treatment of diabetic ketoacidosis and for patients who smoke. It has not yet been tested on people under 18 years of age.
.
The main limitation is the low range of dosages available. There are only three presentations: 4, 8 or 12 units, while injectable insulins are offered in doses of 1 unit, which allows more combination and personalization.
.
It is not yet possible to estimate how much the product will cost in Brazil. In the United States, the lowest dose, 4 units, costs $ 3.80, or about $ 15.